SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-23-004305
Filing Date
2023-01-23
Accepted
2023-01-23 09:44:14
Documents
4
Period of Report
2023-01-23

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea172050-6k_biondvax.htm 6-K 11228
2 PRESS RELEASE DATED JANUARY 23, 2023 ea172050ex99-1_biondvax.htm EX-99.1 22809
3 GRAPHIC ex99-1_001.jpg GRAPHIC 12208
4 GRAPHIC ex99-1_002.jpg GRAPHIC 20166
  Complete submission text file 0001213900-23-004305.txt   79986
Mailing Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000
Business Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-37353 | Film No.: 23542777
SIC: 2836 Biological Products, (No Diagnostic Substances)